Bristol-Myers Squibb's flurry of dealmaking has continued with en expansion of its partnership with BridgeBio on drugs targeting SHP2, in the hope of combining them with its cancer immunotherapy ...

BMS CEO Christopher Boerner said the company is confident relying on pipeline assets to cover revenues to be lost with patent expiries for Opdivo and Eiquis. Credit: PixelBliss/Shutterstock.com ...

Not ones to sit around and waste time, New Jersey’s very own thrash metal icons Overkill are back at the studio writing new music for their follow-up to 2023’s Scorched. Earlier this week, the band’s ...

Thrash metal stalwarts Overkill are wasting no time moving forward after a major lineup change. Just over a year since releasing Scorched, the New Jersey veterans are already writing and demoing ...

Bristol Myers Squibb (BMS) has agreed to co-develop and co-commercialize BioNTech’s cancer-fighting bispecific antibody candidate BNT327 across numerous solid tumor types through a collaboration that ...

Bristol Myers Squibb, Board Chair of BMS and CEO Christopher Boerner, PhD, have committed the pharma giant to investing $40 billion over the next five years toward U.S. research and development (R&D), ...

Roughly two years after securing a former Novartis facility in Illinois to support its CAR-T cancer treatments Breyanzi and Abecma, Bristol Myers Squibb is rethinking its operations at the site. BMS ...

Details on a BMS based on electrochemical impedance spectroscopy (EIS). BMS advances to keep pace with EV rising complexity. Building better battery models based on EIS characterization. The ...

Bristol Myers Squibb said in its fourth-quarter results update this morning that it will double down on an ongoing cost-cutting programme announced last year. The company still intends to slash $1.5 ...

Publisher Nexon and developer Neople have released two new gameplay videos for 3D action RPG Project OVERKILL as part of G-Star 2024, which runs from November 14 to 17 at Busan Exhibition and ...

For the second time in 19 months, a federal judge in New York has dismissed a lawsuit claiming that Bristol Myers Squibb slow-walked its request for FDA approval of blood cancer drug Breyanzi to avoid ...